AIkido Pharma Inc. to Present at The LD 500 Virtual Conference
AIkido Pharma Inc. (Nasdaq: AIKI) will present at the LD 500 investor conference on September 3, 2020, at 11:20 a.m. ET. CEO Anthony Hayes will speak to a live audience. The event, happening from September 1-4, is notable for being accessible to all attendees due to pandemic restrictions on physical gatherings. AIkido specializes in anti-cancer therapeutics and collaborates with prestigious institutions like The University of Texas at Austin and Wake Forest University to develop innovative therapeutic options for various cancers.
- None.
- None.
NEW YORK, Aug. 14, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 11:20 a.m. ET. Anthony Hayes, CEO of AIkido Pharma Inc. will be presenting to a live audience.
Register here: https://ld-micro-conference.events.issuerdirect.com/
"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space," stated Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.
View AIkido Pharma's profile here: http://www.ldmicro.com/profile/AIKI
Profiles powered by LD Micro — News Compliments of Accesswire
About AIkido
AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.
About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.
What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.
The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido:
Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-to-present-at-the-ld-500-virtual-conference-301112317.html
SOURCE AIkido Pharma Inc.
FAQ
When will AIkido Pharma present at the LD 500 conference?
What is the focus of AIkido Pharma's presentation at the LD 500?
How can I register for the LD 500 investor conference?
What dates is the LD 500 investor conference taking place?
What type of therapies is AIkido Pharma developing?
